SIREN : 498890813
PROVEPHARM HOLDING is a French company founded 18 years ago, specialized in the sector Activités des sièges sociaux. Based in MARSEILLE (13013), this company of category ETI shows in 2024 a revenue of 60 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 60 000 € | 60 000 € | 60 000 € | 60 000 € | 60 000 € | 60 000 € | 77 618 € |
| Net income | 3 375 350 € | 4 443 965 € | 3 534 584 € | 3 226 877 € | 2 225 911 € | 1 878 018 € | 393 268 € |
| EBITDA | -77 973 € | -147 736 € | -51 222 € | -46 989 € | -38 908 € | -77 596 € | -74 534 € |
| Net margin | 5625.6% | 7406.6% | 5891.0% | 5378.1% | 3709.9% | 3130.0% | 506.7% |
In 2024, PROVEPHARM HOLDING achieves revenue of 60 k€. Activity remains stable over the period (CAGR: -3.6%). Slight decline of 0% vs 2023. After deducting consumption (0 €), gross margin stands at 60 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -78 k€, representing -130.0% of revenue. Positive scissor effect: EBITDA margin improves by +116.3 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3.4 M€, i.e. 5625.6% of revenue. This profit can be retained or distributed to shareholders.
60 000 €
60 000 €
-77 973 €
-62 490 €
3 375 350 €
-130.0%
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 90%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 5625.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
11.487%
89.603%
5625.583%
1.676
In 2024, the debt ratio of PROVEPHARM HOLDING (11.49) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of PROVEPHARM HOLDING (89.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of PROVEPHARM HOLDING (1.68) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 7912.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
7912.614
-50.512
In 2024, the liquidity ratio of PROVEPHARM HOLDING (7912.61) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of PROVEPHARM HOLDING (-50.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 161 days. Excellent situation: suppliers finance 161 days of the operating cycle (retail model). Overall, WCR represents 17939 days of revenue, i.e. 3.0 M€ to permanently finance. Over 2017-2024, WCR increased by +922%, requiring additional financing.
2 989 912 €
0 j
161 j
0 j
17939 j
Based on 103 transactions of similar company sales in 2024, the value of PROVEPHARM HOLDING is estimated at 12 850 616 € (range 4 414 241€ - 34 593 533€). The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PROVEPHARM HOLDING with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of PROVEPHARM HOLDING in 2024 is 60 k€.
Yes, PROVEPHARM HOLDING generated a net profit of 3.4 M€ in 2024.
The headquarters of PROVEPHARM HOLDING is located in MARSEILLE (13013), in the department Bouches-du-Rhone.
The tax return of PROVEPHARM HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PROVEPHARM HOLDING operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.